dr john mcmurray: the next step for sglt 2 inhibitors in patients with hf is implementation
Published 4 years ago • 135 plays • Length 3:45Download video MP4
Download video MP3
Similar videos
-
20:13
sglt2 inhibitors in heart failure management with dr. john mcmurray
-
4:40
dr john mcmurray compares emperor-reduced findings with dapa-hf
-
21:36
dr. john mcmurray: new and emerging heart failure therapies
-
3:30
researcher comment: the dapa-hf trial | john mcmurray
-
1:22
dr john mcmurray details the preliminary cost-effectiveness distinction of dapagliflozin
-
25:24
professor john mcmurray - heart failure: pharmacology that extends the limits!
-
1:05
dr john mcmurray: dapagliflozin excels as a preventive and established treatment for heart failure
-
3:50
dr. mcmurray discusses the dapa-hf trial of dapagliflozin in systolic heart failure
-
1:23:55
prof. john mcmurray - what have we learned from the sglt2i trials in heart failure?
-
29:48
professor john mcmurray - heart failure therapy – extending the limits!
-
1:12
results of dapa-hf - dr. john j mcmurray
-
1:05:21
sglt2 inhibitors in heart failure: new analyses and recent updates
-
31:52
managing heart failure: are sglt2 inhibitors the next leap forward in optimizing patient care?
-
3:14
john mcmurray, md: the future is bright for dapagliflozin
-
10:37
cardiovascular outcomes in new users of sglt-2 inhibitors
-
59:02
not so sweet: the link between diabetes and heart failure
-
1:17:28
heart failure in fabry disease dr john jefferies md mph
-
2:44
jonathan roberts, md, facc, fscai - cardiology fellowship
-
15:31
dr. josef stehlik: "recovery, from the myocardium to patient quality of life"